PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.
This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.
Help employers find you! Check out all the jobs and post your resume.
This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.
Help employers find you! Check out all the jobs and post your resume.
